FDA clears OTC continuous glucose monitor for kids

The U.S. Food and Drug Administration (FDA) has cleared for marketing the first over-the-counter (OTC) Continuous Glucose Monitor (CGM) for children. Dexcom Inc.’s Stelo Glucose Biosensor System, an integrated CGM (iCGM), is now indicated for people two years of age and older who do not use insulin. This marks a significant expansion of access to real-time glucose data for a younger, non-insulin-dependent population.

Traditionally, CGMs have been primarily prescribed for individuals managing diabetes with insulin. Expanding OTC access to children as young as two, particularly for those not on insulin, opens new avenues for monitoring and understanding metabolic health in a preventive context. This could be particularly valuable for identifying early signs of pre-diabetes or metabolic dysregulation, allowing for earlier lifestyle interventions. The Stelo system's clearance provides continuous glucose data without a prescription, enabling proactive health management.

With this new OTC option, individuals and families have more direct access to tools for understanding real-time metabolic responses. It empowers proactive health management but also places a greater responsibility on users to interpret data wisely, ideally with professional guidance. For your health and your family's, always prioritize informed decisions alongside such powerful technological aids.